Victoria Allan

Jazz Pharmaceuticals (United States) — United States

Medicine · Health Sciences

11h-index688citations31works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Atrial Fibrillation Management and Outcomes(11), Cancer Immunotherapy and Biomarkers(10), Lung Cancer Treatments and Mutations(8), Acute Myocardial Infarction Research(6), Health Systems, Economic Evaluations, Quality of Life(4)

Publications31 total

Real-world use, effectiveness, and safety of second-line lurbinectedin monotherapy in small cell lung cancer
Future Oncology·2025· 2 citedOpen Access
PP01.117 Real-World Effectiveness and Safety Profile of Lurbinectedin and Other Second-Line Treatments in Small Cell Lung Cancer
Journal of Thoracic Oncology·2024
P2.17-02 EFfectiveness and Safety Profile of Lurbinectedin in Second-Line Small Cell Lung Cancer: A Real-World Study
Journal of Thoracic Oncology·2023Open Access
IO-Synthesise RCC: Real-world outcomes with nivolumab in previously treated advanced renal cell carcinoma, a pooled analysis of patients from France and Germany
European Urology Open Science·2021Open Access
1348P Long-term survival and health-related quality of life with nivolumab for previously-treated advanced non-small cell lung cancer (NSCLC): A wide prospective French real-world study (EVIDENS)
Annals of Oncology·2021
Videos for MRC5 cells stably expressing GFP-Rab5
Zenodo (CERN European Organization for Nuclear Research)·2021Open Access
Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada
Lung Cancer·2021· 23 citedOpen Access
IO-Synthesise RCC: A pooled analysis of real-world outcomes for advanced renal cell carcinoma patients treated with nivolumab in France and Germany
European Urology Open Science·2020Open Access
1325P Long-term survival and health-related quality of life in patients treated with nivolumab for advanced non-small cell lung cancer: A wide prospective French real-world study (EVIDENS)
Annals of Oncology·2020
Two-year survival with nivolumab in previously treated, advanced non-small cell lung cancer: A pooled analysis of real-world patients from France, Germany and Canada.
Journal of Clinical Oncology·2020
Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants
Journal of Comparative Effectiveness Research·2020· 167 citedOpen Access
Factors associated with non-prescription of oral anticoagulant treatment in non-valvular atrial fibrillation patients with dementia: a CPRD–HES study
Age and Ageing·2020· 15 citedOpen Access
Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study
OncoImmunology·2020· 38 citedOpen Access
Bleeding in cardiac patients prescribed antithrombotic drugs: electronic health record phenotyping algorithms, incidence, trends and prognosis
BMC Medicine·2019· 19 citedOpen Access
Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: Updated survival and subgroup analysis from the real-world EVIDENS study
Annals of Oncology·2019· 2 cited
IO-synthesise NSCLC: A pooled analysis of real-world survival outcomes for non-small cell lung cancer patients treated with nivolumab in France and Germany
Annals of Oncology·2019· 2 citedOpen Access
Subtypes of atrial fibrillation with concomitant valvular heart disease derived from electronic health records: phenotypes, population prevalence, trends and prognosis
EP Europace·2019· 28 citedOpen Access
Impact of Atrial Fibrillation Awareness Campaigns: Interrupted Time Series Using the Clinical Practice Research Datalink
Future Cardiology·2019Open Access
PCN6 REAL WORLD EFFECTIVENESS OF NIVOLUMAB IN ASIAN PATIENTS IN THE UNITED STATES FLATIRON HEALTH DATABASE
Value in Health·2019
Health-related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) patients treated with nivolumab in real-life: The EVIDENS study
Annals of Oncology·2019· 5 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Fabrice Barlési(8), D. Debieuvre(8), Denis Moro‐Sibilot(8), Clarisse Audigier-Valette(8), M. Pérol(8), A. Dixmier(7), C. Raspaud(7), Bernard Asselain(7), Sreeram V Ramagopalan(6), J.B. Auliac(6), P. Bombaron(6), C. Calvet(6), Amitava Banerjee(5), Harry Hemingway(5), Nicolas Benoît(5), D. Reynaud(5), Anoop D Shah(4), Spiros Denaxas(4), FE Cotté(4), Chris P Gale(3)